Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of #ProstateCancer . A systematic review and meta-analysis. #BeyondTheAbstract with Cassie Huang University of Melbourne on UroToday > bit.ly/3INrGUC Prostate Cancer and Prostatic Diseases

#ASCO24 is quickly approaching! If you haven't already, don't forget to sign up for email coverage delivered straight to your inbox! #FollowUs on #SoMe to stay up to date for upcoming events and live coverage throughout the conference > bit.ly/3QbtkmW ASCO #ASCO2024

Navigating the Nuances: Exploring imaging options and impact to treatment strategies in #nmCPRC . Ryan Malone, MD First Urology joins Zach Klaassen Georgia Cancer Center in this conversation focusing on the evolving role of PSMA PET imaging. #WatchNow > bit.ly/42lRAaT Bayer U.S. 🇺🇸

Utilization of neoadjuvant chemo before cystectomy. Hiten Patel NM Urology joins Ruchika Talwar Vanderbilt Urology to discuss his team’s study on the use of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive #BladderCancer . #WatchNow > bit.ly/3IQNe2D

Defining standard and extended pelvic lymphadenectomy in #BladderCancer surgery. Seth Lerner, MD, FACS BCMHouston & Sia Daneshmand, M.D. Keck Medicine of USC join Patrick Hensley, MD as part of the IBCG #BladderCancer Forum in this discussion on UroToday > bit.ly/3VjRpuM

#COBRA Trial shows promise for copper-64 PSMA PET in biochemical recurrence. Neal Shore CURC joins Phillip Koo, MD Banner Health to discuss promising initial findings and the potential of this technology to improve clinical outcomes > bit.ly/3wUMRSw CLARITY

Advances in #PrecisionMedicine rapidly transforming treatment options for #BladderCancer patients. Daniel Castellano Hospital Universitario 12 de Octubre discusses the importance of multidisciplinary approaches in patient care and research > bit.ly/3SvJ7yD

#ARAMON trial: Darolutamide monotherapy and testosterone levels in biochemically recurrent #ProstateCancer . Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center and Zach Klaassen Georgia Cancer Center discuss in this conversation on UroToday > bit.ly/3W56VM6

Treatment decision making in #mCRPC : The #Urologist and #Patient “What the patient needs to know” about his disease and treatment options? Brenda Martone Lurie Cancer Center joins Neal Shore in this independent medical education initiative > bit.ly/47IaNW2 Loxo@Lilly Oncology Medical

Maximizing survival in #mHSPC : The role of triplet therapy. Kelvin Moses, MD, PhD Vanderbilt-Ingram Cancer Center joins Zach Klaassen Georgia Cancer Center to discuss the ideal patient profile and emphasize collaboration between #Urology and #MedicalOncology > bit.ly/4b06kzn

Distinct mesenchymal cell states mediate #ProstateCancer progression. Massimo Loda Weill Cornell Medicine Pathology and Andrea Miyahira Prostate Cancer Foundation discuss his team’s research on the role of the microenvironment in #PCa progression, published in Nature Communications > bit.ly/4cnAu19 NewYork-Presbyterian

The role of radiotherapy in the management of squamous cell cancer of the penis. #BeyondTheAbstract with Juanita Crook, MD, FRCPC BC Cancer of work in @WJUrol. #ReadNow on UroToday > bit.ly/4cjm0iQ

Exciting Insights on #ProstateCancer Resistance! 🦠 Join Andrea Miyahira and Ping Mu 🇺🇦 as they delve into groundbreaking research on anti-androgen resistance and the role of UBE2J1 in regulating AR degradation and its impact on therapy resistance > bit.ly/47IlEPj

Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent #ProstateCancer . #BeyondTheAbstract with Francesca Ambrosini and Tobias Maurer on UroToday > bit.ly/4aQbtu7 Martini-Klinik am UKE European Association of Nuclear Medicine (EANM)

Novel computational approach identifies NME2-MYC axis as a biomarker and therapeutic target in enzalutamide-resistant #CRPC . Antonina Mitrofanova, PhD SHP_Rutgers joins Andrea Miyahira to discuss her teams research in Nature Communications > bit.ly/4bjJjrz

CheckMate-214 at 8 years: Nivolumab + ipilimumab shows durable survival benefit in advanced #RCC . Nizar Tannir, MD, FACP MD Anderson Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss 8yr results in this conversation on UroToday > bit.ly/3UeuE9Q

PSMA PET as a biomarker for advanced #ProstateCancer . Oliver Sartor Mayo Clinic joins Neal Shore, MD, FACS CURC to present as part of this independent medical education initiative supported by Loxo@Lilly Oncology Medical > bit.ly/40GJjO8

Alpha vs beta emitters in #ProstateCancer radiopharmaceuticals: Energy, range, and cytotoxicity. Alan H Bryce City of Hope joins Alicia Morgans, MD, MPH Dana-Farber in this discussion of radiopharmaceutical therapies for #mCRPC with bone metastases > bit.ly/3UuDd1T

PARP inhibitors: Targeting DNA repair pathways. Neal Shore, MD, FACS CURC joins Fred Saad, MD, FRSC CHUM in this presentation as part of an independent medical education initiative supported by Loxo@Lilly Oncology Medical > bit.ly/3ugB4w2

Pending #LBAs , my Top* 10 #ASCO24 (so far) are:

*list heavily GU-skewed

Dana-Farber ASCO